UVA-Riboflavin Crosslinking Treatment of Corneal Ectasia

Keratoconus Clinical Trial

Official title:

UVA-Riboflavin Crosslinking Treatment of Corneal Ectasia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01325298
• Other study ID #: IND 109752
• Status: Recruiting
• Phase: Phase 2
• First received: March 28, 2011
• Last updated: March 28, 2011
• Start date: March 2011
• Est. completion date: May 2014

Study information

• Verified date: March 2011
• Source: Mercy Center for Corrective Eye Surgery
• Contact: Charisse Haas
• Phone: 815-363-2020
• Email: chaas[@]mhsjvl.org
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate two different ultraviolet (UV) dosing regimens for corneal collagen cross linking to slow the progressive changes in corneal curvature in eyes with progressive keratoconus or post-refractive surgery ectasia.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 250
• Est. completion date: May 2014
• Est. primary completion date: March 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 14 Years to 55 Years

Eligibility

Inclusion Criteria:

i. Age 14 years or older for keratoconus subjects since disease often begins at puberty, and 18 years or older for post-refractive surgery keratectasia and post-transplant patients

ii. Signed, dated, written informed consent

iii. Having documented ectasia on topography or tomography after previous refractive surgery OR progressive keratoconus defined as one or more of the following changes over a period of 24 months or less before randomization:

• An increase of at least 1.0 diopter in the steepest keratometry value (or sim K), or

• an increase of at least 1.0 diopter in regular astigmatism evaluated by subjective manifest refraction, or

• a myopic shift (decrease in the spherical equivalent) of at least 0.5 diopters on subjective refraction, or

• documented decrease in visual acuity associated with irregular astigmatism and topographic features of ectasia

iv. Have minimal preoperative corneal thickness of 375 microns or more, as measured in the office with epithelium not yet removed

v. For subjects with non-post refractive surgery keratoconus diagnosis only:

• 14 years or older to 55 years of age,

• axial topography consistent with keratoconus such as presence of abnormal central or paracentral steepening on the corneal topography map, or presence of one or more slit lamp findings associated with keratoconus, such as

• Fleischer ring

• Vogt striae

• Corneal thinning

• Corneal scarring

vi. For contact lens wearers only:

Removal of contact lenses for the required period of time prior to final screening refraction:

• Contact lens minimum discontinuation time two weeks for soft, extended wear, soft toric, and rigid gas permeable lenses

vii. For patients with post-refractive surgery keratectasia:

• History of excimer laser refractive surgery with increasing refractive astigmatism and corneal topographic or keratometric astigmatism of 0.5 or more, or a history of decreasing best spectacle corrected visual acuity associated with the presence of topography suggestive of keratoconus or pellucid marginal degeneration or abnormal higher order aberrations (especially coma) on the aberration mapping of the eye.

viii. For patients with corneal transplants:

• History of corneal transplant for keratoconus with documented increasing refractive astigmatism and corresponding topographic irregularity occurring at least one year after corneal transplantation, not attributable to transplant suture removal and occurring during the most recent two years.

Exclusion Criteria:

i. Patients with excessively thin corneas. (Intraoperative minimal corneal thickness in the swollen state with the epithelium removed must exceed 400 microns)

ii. Keratometric readings greater than 62D

iii. No evidence of keratoconus/keratectasia progression over the prior three years

iv. Age less than 55 years but under

• 14 years for keratoconus patients

• 18 years for post-refractive surgery keratectasia and post-transplant patients

v. Previous ocular condition in the eye(s) to be treated that might, in the investigator's opinion, predispose to complications (such as history herpes simplex keratitis, corneal melt, perforated corneal ulcer, descemetocele, prior corneal damage from chemical injury, herpes zoster keratitis, nystagmus, corneal scarring that significantly impairs vision, pre-existing glaucoma, glaucoma suspect, Goldmann applanation pressure exceeding 23 mm Hg, cataract, history of uveitis, active ocular disease that might lead to infection, corneal endothelial cell count below 1800 cells per square millimeter)

vi. Patients with a systemic condition that, in the investigator's opinion, might predispose to complications (such as Down syndrome, autoimmune disease, pregnancy or nursing at the time of initial treatment, history of alcohol abuse, being immunocompromised, allergy to riboflavin or other study medications)

vii. Patients who are unwilling or unable to comply with the study regimen and doctor's advice

viii. Patients unwilling to discontinue wear of rigid contact lenses in the eye to be operated on for at least one month before baseline examination, and for the first six months post-operatively

ix. Patient unwilling to discontinue contact lenses prior to baseline exam: one week for soft lenses, two weeks for rigid or soft toric lenses

x. Pregnancy at the time of proposed crosslinking

xi. Known hypersensitivity to riboflavin

xii. Central corneal endothelial cell count below 1400 cells per square millimeter.

xiii. Presence of significant central corneal stromal scar

xiv. History of delayed wound healing

xv. Immunocompromised patient

xvi. History of connective tissue disease (such as systemic lupus erythematosus, rheumatoid arthritis)

xvii. History of glaucoma, a Goldmann applanation pressure measured in keratoconus evaluation of above 24, or glaucoma suspect, xviii. Significant existing cataract

xix. Macular degeneration or confluent drusen of Bruchs membrane

xx. Evidence of past or present herpes simplex of the cornea

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Corneal Diseases
• Corneal Ectasia
• Ectasia
• Keratoconus

Intervention

Device:
• UV-X Light
UV-X 365 nm wavelength light source is applied to the cornea with continued application of riboflavin 0.1%

Drug:
• Riboflavin
Riboflavin 0.1% is applied to the cornea every 2 minutes for 14 minutes prior to and also during UV-X Light treatment.

Device:
• UV-X Light
UV-X 365 nm wavelength light source is applied to the cornea with continued application of riboflavin 0.1%

Drug:
• Riboflavin
Riboflavin 0.1% is applied to the cornea every 2 minutes for 14 minutes prior to and also during UV-X Light treatment.

Locations

Country	Name	City	State
United States	Mercy Center for Corrective Eye Surgery	McHenry	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
Mercy Center for Corrective Eye Surgery

Country where clinical trial is conducted

United States, 

References & Publications (6)

Caporossi A, Baiocchi S, Mazzotta C, Traversi C, Caporossi T. Parasurgical therapy for keratoconus by riboflavin-ultraviolet type A rays induced cross-linking of corneal collagen: preliminary refractive results in an Italian study. J Cataract Refract Surg — View Citation

Caporossi A, Mazzotta C, Baiocchi S, Caporossi T. Long-term results of riboflavin ultraviolet a corneal collagen cross-linking for keratoconus in Italy: the Siena eye cross study. Am J Ophthalmol. 2010 Apr;149(4):585-93. doi: 10.1016/j.ajo.2009.10.021. Ep — View Citation

Goldich Y, Marcovich AL, Barkana Y, Avni I, Zadok D. Safety of corneal collagen cross-linking with UV-A and riboflavin in progressive keratoconus. Cornea. 2010 Apr;29(4):409-11. doi: 10.1097/ICO.0b013e3181bd9f8c. — View Citation

Mazzotta C, Traversi C, Baiocchi S, Sergio P, Caporossi T, Caporossi A. Conservative treatment of keratoconus by riboflavin-uva-induced cross-linking of corneal collagen: qualitative investigation. Eur J Ophthalmol. 2006 Jul-Aug;16(4):530-5. — View Citation

Raiskup-Wolf F, Hoyer A, Spoerl E, Pillunat LE. Collagen crosslinking with riboflavin and ultraviolet-A light in keratoconus: long-term results. J Cataract Refract Surg. 2008 May;34(5):796-801. doi: 10.1016/j.jcrs.2007.12.039. — View Citation

Wittig-Silva C, Whiting M, Lamoureux E, Lindsay RG, Sullivan LJ, Snibson GR. A randomized controlled trial of corneal collagen cross-linking in progressive keratoconus: preliminary results. J Refract Surg. 2008 Sep;24(7):S720-5. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in corneal curvature	Measured by maximum keratometry (Kmax)	6 months	No
Secondary	corrected distance acuity	best spectacle corrected distance acuity	6 months	No
Secondary	corneal endothelial cell count		6 months	Yes
Secondary	pachymetry	Minimal corneal thickness	6 months	No

External Links

•   Educational material in website of Mercy Center for Corrective Eye Surgery